Praetego is committed to offering clinically meaningful drug candidates to patients at risk for serious diabetic complications; something that limits disease progression. Praetego’s candidates (the Amadorins) are proprietary small molecules that inhibit the first step in the AGE pathway, a critical stage in limiting disease progression.



Serious Diabetic Complications

Serious Diabetic Complications stem from chronic insults to the vascular system from high blood glucose. This leads to damage of organs and tissues nourished by the microvascular system, including the nerves, kidneys, and eyes. Diabetic Peripheral Neuropathy, Nephropathy (Kidney Disease), and Retinopathy negatively impact quality of life. Without a way to slow or prevent damage to blood vessels, these conditions can become life threatening. Serious Diabetic Complications significantly increase the cost of care and decrease quality of life.

While there are many drugs to manage glucose control, there are almost none able to impact disease progression. Praetego’s mission is to develop a first in class disease modifying agent for the 34M Americans living with Diabetes.


AGE Pathway

Diabetic microvascular damage is caused by a cascade of biochemical reactions called the AGE Pathway. Advanced Glycation End-products are named for their constituents. Advanced indicates the terminal nature of the compounds produced by the pathway. Glucose binds with proteins, lipids and DNA through glycation. AGEs are instigators of pathology. Once formed, they are irreversible. As AGEs accumulate in tissue, they signal an inflammatory response and impact tissue integrity. The result can be organ damage or destruction. [See video Role of AGEs]


Amadorins Inhibit the AGE Pathway

Praetego’s Amadorin technology inhibits AGE formation at the initial step. They function as chemical protectants and inhibit the reaction that drives AGE formation. By intervening at the initial step, an Amadorin drug candidate could limit all of the downstream consequences – Neuropathy, Nephropathy, Retinopathy, and Cognitive Decline.